MolDX: Melanoma Risk Stratification Molecular Testing

Molecular risk-stratification tests for melanoma are covered only for patients with a personal history of melanoma who are undergoing workup/treatment evaluation, are non-metastatic, and have tumor characteristics (T1b+ or T1a with inadequate microstaging) and an estimated SLNB risk >5% within the test's intended use. Coverage also requires that the specific test demonstrates clinical validity, clinical utility beyond standard clinical/histologic/radiographic factors, appropriate analytical validity, and equivalent or superior performance to other covered tests.

"Patient has a documented personal history of melanoma."

Sign up to see full coverage criteria, indications, and limitations.